Cardiovascular risk prediction in #RA using #AI chest xray imaging improves accuracy abst#0146 @RheumNow #EULAR2024 https://t.co/wtF5Sel8Tx

• https://twitter.com/bella_mehta/status/1801177426245861631/photo/1
• https://twitter.com/bella_mehta/status/1801177426245861631/photo/1
• https://twitter.com/bella_mehta/status/1801177426245861631/photo/1
• https://twitter.com/bella_mehta/status/1801177426245861631/photo/1

RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks !@rheumnow #EULAR2024

steroid dose 120 mg , repeated if not in remission 12 wks on background MTX - no difference between groups @rheumnow #EULAR2024 https://t.co/gkqmElfOCp

• https://twitter.com/drpnash/status/1801189627220381773/photo/1

Deep learning to predict if an #RA patient will benefit from treatment using MRIs abst#0182 Models are still not good for mainstream practice- but will be in the future! Lots of fine tuning required #EULAR2024 #EULARBest @rheumnow https://t.co/9yVN6CHLCv

• https://twitter.com/bella_mehta/status/1801186257407475812/photo/1
• https://twitter.com/bella_mehta/status/1801186257407475812/photo/1
• https://twitter.com/bella_mehta/status/1801186257407475812/photo/1
• https://twitter.com/bella_mehta/status/1801186257407475812/photo/1

dual IL 17 A & F nanobody typical response at 12 wks not significantly better - how many IL17 inhibs do we need? ⁦@RheumNow⁩ #EULAR2024 https://t.co/50dIKyO0e4

• https://twitter.com/drpnash/status/1801192552428630122/photo/1

Was a full room #EULAR2024 for the SELECT-GCA presentation (upadacitinib in GCA positive study). Palpable excitement through the audience here in Vienna @RheumNow https://t.co/bFL6mqqFAa

• https://twitter.com/drdavidliew/status/1801196482995101974/photo/1

Using data from a large population > 100 million people with SpA (predominantly PsA) from the TriNetX Global Collaborative Network, JAKi was not associated with increased risk of CVD, VTE or selected cancers, compared to TNFi or IL-17i #EULAR2024 Abstract P0231 @RheumNow https://t.co/Oi64BeWcmk

• https://twitter.com/synovialjoints/status/1801304164498292784/photo/1

Patients with r-axSpA can be divided into subgroups with specific pain distribution profiles and sensory symptom profiles (Clusters 1,2,3) 1 with a diffuse distribution of pain over many pain regions indicates activation of the nociplastic pain mechanisms, 2 with pain localised… https://t.co/HsaBzlXzoc https://t.co/CpMPzNWptk

• https://twitter.com/i/web/status/1801302327120294296
• https://twitter.com/synovialjoints/status/1801302327120294296/photo/1

Molecular dissection of OA mechanisms brings some important pieces of knowledge and new potential therapeutic targets GWAS in hands OA #EULAR2024 @RheumNow https://t.co/L7iZgzmFtr

• https://twitter.com/AurelieRheumo/status/1801285412251382173/photo/1

Get your sunscreen ready 🌞! Higher UV-B exposure asso w/ higher chance of reaching ACR/EULAR Boolean remission in RA pts treated w/ MTX monotherapy Now this could well be a surrogate for other socio demographic factors asso with better prognosis @RheumNow #EULAR2024 OP0153 https://t.co/k852O5psTM

• https://twitter.com/AurelieRheumo/status/1801284385628377404/photo/1

Nationwide turkish cohort study e.PULSE 347000+ pts Gender based comorbidity analysis Female asso w/ higher -accompanying CTD OR 3.75 -asthma OR 2.06 -depression OR 2.38 -fibromyalgia OR 3.16 and lesser - COPD OR 0.34 - ILD OR 0.60 -Malignancy OR 0.63 @RheumNow #EULAR2024 OP0175

When to administrate the PCV13 in RA? VACIMRA study 276pts randomized PCV13 + MTX = 75% humoral response PCV13 + MTX 1 month later = 88% humoral response No diff on dis control & GCs or DMARDs use #EULAR2024 @RheumNow AbstOP0140

#EULARBest @RheumNow https://t.co/cCv88iTCTV

• https://twitter.com/AurelieRheumo/status/1801276696655503661

ARGO trial Ph 2 RCT Sonelokimab IL-17A/Fi Nanobody Wk 12, primary ACR50 ACR 50 SON 120 mg 46% 60 mg 46% PBO 20% PASI 90 SON 120 mg 60% 60 mg 77% PBO 15% MDA SON 60mg 47% PBO 20% No new safety signal #EULAR2024 @RheumNow AbstrOP0195 https://t.co/4W5KFi23za

• https://twitter.com/AurelieRheumo/status/1801280906679705656/photo/1